Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Ocugen(OCGN) Newsfilter·2025-01-13 19:30100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one yearImprovement in visual function was statistically significant (p=0.01, treated vs untreated eyes), regardless of mutation at two yearsFavorable long-term safety and tolerability profile with no serious adverse events ...